- Home
- KYMR vs RYTM Comparison
KYMR vs RYTM Comparison
Compare KYMR & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYMR | RYTM |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.4B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | KYMR | RYTM |
|---|---|---|
| Price | $87.70 | $95.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 24 | 14 |
| Target Price | $105.96 | ★ $131.00 |
| AVG Volume (30 Days) | ★ 707.0K | 606.2K |
| Earning Date | 04-03-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,072,000.00 | N/A |
| Revenue This Year | $19.43 | $47.98 |
| Revenue Next Year | N/A | $56.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.45 | $45.91 |
| 52 Week High | $103.00 | $122.20 |
Technical Indicators
Market Signals| Indicator | KYMR | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 68.85 | 39.90 |
| Support Level | $77.78 | $83.98 |
| Resistance Level | $103.00 | $96.92 |
| Average True Range (ATR) | 3.97 | 5.46 |
| MACD | 1.00 | -0.45 |
| Stochastic Oscillator | 86.86 | 2.72 |
Price Performance
Historical ComparisonAbout KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.